SANGUINE CORP. (SGNC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mr. Forthright who wrote (1518)	6/20/1998 10:35:00 PM
From: chirodoc	Read Replies (1) of 5402

THERE ARE PROBLEMS WITH HEMOGLOBIN SUBSITUTES.... .FROM NONE OTHER THAN FDA! YOU CAN SEE WHY DR. D MAY HAVE A BETTER ANSWER WITH PHER-02! Mol Med Today 1995 Jun;1(3):122-127 Hemoglobin and free radicals: implications for the development of a safe blood substitute. Alayash AI, Cashon RE Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA. Alayash@A1.CBER.FDA.GOV The two major concerns in the development of cell-free hemoglobin as a blood substitute (i.e. circulatory retention and oxygen delivery) have been resolved successfully by strategic chemical or genetic modification of the protein. However, the redox reactivity of hemoglobin and its impact on the physiological processes has not been fully understood, nor has it been subject to control by design. This article reviews current research into heme-mediated toxicities that potentially constitute serious impediments to the development of a usable blood substitute.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next